Share on StockTwits

Stemline Therapeutics (NASDAQ:STML) CEO Ivan Bergstein acquired 2,000 shares of the stock in a transaction dated Wednesday, September 3rd. The stock was purchased at an average price of $11.05 per share, for a total transaction of $22,100.00. Following the transaction, the chief executive officer now directly owns 1,903,955 shares in the company, valued at approximately $21,038,703. The purchase was disclosed in a legal filing with the SEC, which is available at this link.

Shares of Stemline Therapeutics (NASDAQ:STML) traded down 3.23% during mid-day trading on Friday, hitting $10.50. 55,843 shares of the company’s stock traded hands. Stemline Therapeutics has a 1-year low of $10.509 and a 1-year high of $47.25. The stock has a 50-day moving average of $11.56 and a 200-day moving average of $16.32. The company’s market cap is $135.9 million.

Stemline Therapeutics (NASDAQ:STML) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.47) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.71) by $0.24.

Stemline Therapeutics, Inc (NASDAQ:STML) is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk.

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with Analyst Ratings Network's FREE daily email newsletter.